Ken Griffin Terns Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 129,400 shares of TERN stock, worth $860,510. This represents 0.0% of its overall portfolio holdings.
Number of Shares
129,400
Previous 63,900
102.5%
Holding current value
$860,510
Previous $435,000
148.05%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding TERN
# of Institutions
163Shares Held
78.4MCall Options Held
450KPut Options Held
423K-
Orbimed Advisors LLC San Diego, CA7.56MShares$50.3 Million1.49% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$45.9 Million8.42% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.22MShares$41.4 Million4.41% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$37.1 Million1.71% of portfolio
-
Black Rock Inc. New York, NY4.12MShares$27.4 Million0.0% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $250M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...